Tekturna and Aliskiren Lawsuits
On February 17, 2012 the drug company Novartis reported that it would revise the drug labeling of Aliskiren, marketed as Tekturna in the United States, after early results from a study revealed and increase incidence of strokes, kidney complications, hyperkalemia, and low blood pressure after 18-24 months of use.
The European Medicines Agency (EMA) also requested that Novartis warn against the use of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) when using Aliskiren.
The ALTITUDE study, where Novartis was examining the use of Tekturna with ACE inhibitors and ARB, was terminated in December 2011 after learning of these unexpected results. Patients using Tekturna with an ACE inhibitor or an ARB are recommended to contact their doctors immediately.
Serving Clients Nationwide
Side effects of Aliskiren
Aliskiren is sold under the name Tekturna in the United States. It has been shown to cause the following problems in users:
- Non-fatal strokes
- Kidney complications
- Hypotension (Low blood pressure)
If you have taken prescription Tekturna and are experiencing any above it is vital to seek immediate medical attention.
Your Legal Rights
Individuals who suffer from these complications as a result of Tekturna use may be entitled to recover compensation related to their losses and injuries, including medical expenses, lost wages or earning capacity, mental anguish, and more. If you or someone you love has developed heart problems that you think may be related to Tekturna, you need to ensure your legal rights are protected.